Ligand director Kozarich proposes $159K share sale

Available on EDGAR 11/12/2026 - 09:11 AM EST Accepted by SEC EDGAR 11/12/2026 - 09:10 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

John Kozarich, a director of Ligand Pharmaceuticals Inc. (LGND), reported a proposed sale of 500 common shares with an aggregate market value of $158,659.25. The notice lists UBS Financial Services, Inc. as broker and an approximate sale date of November 11, 2026. Kozarich acquired 250 shares through a stock award on May 25, 2018 and another 250 through a stock award on June 6, 2025. It lists August 12, 2026 as the date of plan adoption or giving of instruction, if relying on Rule 10b5-1.

Key Figures

Common shares proposed for sale: 500 shares Aggregate market value: $158,659.25 Approximate sale date: November 11, 2026 +3 more

6 metrics

Common shares proposed for sale 500 shares Approximate sale date November 11, 2026

Aggregate market value $158,659.25 Proposed sale of common shares

Approximate sale date November 11, 2026 Proposed sale

Plan adoption or instruction date August 12, 2026 If relying on Rule 10b5-1

Shares acquired through stock award 250 shares May 25, 2018

Shares acquired through stock award 250 shares June 6, 2025

Key Terms

Rule 10b5-1, Aggregate Market Value, Stock Award

3 terms

Rule 10b5-1 regulatory

"if relying on Rule 10b5-1"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

Aggregate Market Value financial

"Aggregate Market Value"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

Stock Award financial

"Nature of Acquisition Transaction: Stock Award"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many LGND shares did John Kozarich propose to sell, and for what value?

John Kozarich, a director, reported a proposed sale of 500 common shares with an aggregate market value of $158,659.25.

When is John Kozarich's proposed LGND sale listed, and which broker is named?

The notice lists an approximate sale date of November 11, 2026 and names UBS Financial Services, Inc. as broker.

What Rule 10b5-1 date does the LGND notice list?

The form lists August 12, 2026 as the date of plan adoption or giving of instruction, if relying on Rule 10b5-1.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001223000
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	LIGAND PHARMACEUTICALS INC
SEC File Number	001-33093
Address of Issuer	3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CALIFORNIA 92121
Phone	858-550-7500
Name of Person for Whose Account the Securities are To Be Sold	KOZARICH JOHN W
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services, Inc. Eleven Madison Avenue 4th Floor New York NY 10010	500	158659.25	20002986	11/11/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/25/2018	Stock Award	Issuer			250	05/25/2018	NA
Common	06/06/2025	Stock Award	Issuer			250	06/06/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	11/12/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	08/12/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ UBS Financial Services Inc, as attorney-in-fact for John Kozarich
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)